A study of readmission rates by primary care providers (PCPs) finds a lack of variation and calls into question implementing pay-for-performance programs that incentivize or penalize PCPs for readmissions.
The Hospital Readmissions Reduction Program from CMS may have successfully reduced readmissions among Medicare beneficiaries, but research has shown that the success has been mixed. JAMA published a study in December 2018 that showed postdischarge mortality increased for beneficiaries hospitalized for heart failure and pneumonia,1 and a Health Affairs study from April 2018 showed that hospitals that serve a large number of minority patients disproportionately receive penalties for readmission rates.2
Now, new research in Annals of Internal Medicine has taken a look at variation in readmission rates among primary care providers (PCPs).3 The researchers studied Texas Medicare claims from 2008 to 2015 for patients discharged between January 1, 2008, and November 30, 2015 who had a PCP in the year prior. They also only included patients whose PCP had at least 50 admissions during the study period.
“Risk for readmission might be influenced by the physicians providing care,” the authors noted. They added that “whether PCP care influences readmissions is uncertain, although CMS has implemented a policy incentivizing PCPs to reduce readmissions.”
The study included 2 cohorts: 1 to study 30-day readmission rates, and 1 to study whether patients were seen by their PCP within 7 days of discharge. A total of 565,579 patients and 4230 PCPs were included.
Higher adjusted readmission rates were associated with being older, male, ineligible for Medicaid, an emergency or weekend admission, nursing home residence, higher diagnosis-related group weight, and more inpatient or ambulatory care episodes in the past year. However, the authors noted that the associations were mostly of small magnitude.
The average risk-standardized readmission rate for the PCPs was 12.9%, and the researchers found there was little variation—the minimum was 11.2% and the maximum was 15.3%. No PCPs had a rate that was statistically significantly lower than the average, and only 1 PCP had a rate that was statistically significant higher.
Overall, 20.4% of beneficiaries saw their PCP within 7 days of hospital discharge. These patients were more likely to be older, Hispanic, or male; had an emergency admission; had multiple physician visits in the past year; or resided in an area with a higher proportion of adults with a high school education. There was more variation among the rates of PCPs seeing patients within 7 days, with 14% having adjusted follow-up rates significantly above average and 16% having rates significantly below.
According to the researchers, the findings have important implications for health policy, considering the Merit-based Incentive Payment System (MIPS) was launched with an underlying assumption that readmission rates vary by PCP. MIPS uses penalties and incentives to incentivize PCPs to reduce readmissions by changing their practice patterns.
“Our finding of minimal variation in risk for readmission among PCPs calls into question any pay-for-performance program that aims to reduce readmissions and assumes variation by PCP,” the authors wrote.
References
1. Wadhera RK, Joynt Maddox KE, Wasfy JH, Haneuse S, Shen C, Yeh RW. Association of the Hospital Readmissions Reduction Program with mortality among Medicare beneficiaries hospitalized for heart failure, acute myocardial infarction, and pneumonia. JAMA. 2018;320(24):2542-2552. doi:10.1001/jama.2018.19232.
2. Figueroa JF, Zheng J, Orav EJ, Epstein AM, et al. Medicare program associated with narrowing hospital readmission disparities between black and white patients. Health Aff (Millwood). 2018;37(4):654-661. doi: 10.1377/hlthaff.2017.1034.
3. Singh S, Goodwin JS, Zhou J, Kuo Y-F, Nattinger AB. Variation among primary care physicians in 30-day readmissions [published online May 21, 2019]. Ann Intern Med. doi: 10.7326/M18-2526.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More